Literature DB >> 18096433

rAAV-asPLB transfer attenuates abnormal sarcoplasmic reticulum Ca2+ -ATPase activity and cardiac dysfunction in rats with myocardial infarction.

Xiao-Yan Zhao1, Shen-Jiang Hu, Jiang Li, Yun Mou, Ka Bian, Jian Sun, Zhao-Hui Zhu.   

Abstract

BACKGROUND: Diminished myocardial sarcoplasmic reticulum Ca(2+)-ATPase (SERCA) activity and upregulated phospholamban (PLB) level during cardiac dysfunction, had been reported in many studies. AIMS: The current study was designed to examine the effects of rAAV-antisense phospholamban (asPLB) gene transfer on cardiac function, SERCA expression and activity, as well as PLB expression and phosphorylation (Pser16-PLB), in a rat myocardial infarction (MI) model. METHODS AND
RESULTS: Rat MI model was generated by ligating the left anterior descending coronary artery. Four weeks later, left ventricular ejection fraction (LVEF), left ventricular systolic pressure (LVSP), the maximal rates of increase and decrease in intraventricular pressure (+/-dp/dt(max)) were significantly depressed, and left ventricular end diastolic pressure (LVEDP) was increased. Myocardial PLB was markedly increased while both SERCA activity and Pser16-PLB level were decreased. In rAAV-asPLB transfected rats, rAAV-asPLB, which was injected into the myocardium around the infarction area immediately after the coronary artery ligation, effectively attenuated the depression of cardiac function, significantly inhibited the expression of PLB, restored Pser16-PLB level and enhanced myocardium SERCA activity.
CONCLUSION: rAAV-asPLB transfer in rats with MI effectively prevented the progression of heart failure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18096433     DOI: 10.1016/j.ejheart.2007.10.013

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  3 in total

1.  Cardiac gene transfer of short hairpin RNA directed against phospholamban effectively knocks down gene expression but causes cellular toxicity in canines.

Authors:  Lawrence T Bish; Meg M Sleeper; Caryn Reynolds; Jeffrey Gazzara; Elanor Withnall; Gretchen E Singletary; George Buchlis; Daniel Hui; Katherine A High; Guangping Gao; James M Wilson; H Lee Sweeney
Journal:  Hum Gene Ther       Date:  2011-06-08       Impact factor: 5.695

2.  AAV-mediated gene therapy for heart failure: enhancing contractility and calcium handling.

Authors:  Fouad A Zouein; George W Booz
Journal:  F1000Prime Rep       Date:  2013-08-01

Review 3.  Nanomedicine for Gene Delivery for the Treatment of Cardiovascular Diseases.

Authors:  Cen Yan; Xiao-Jiang Quan; Ying-Mei Feng
Journal:  Curr Gene Ther       Date:  2019       Impact factor: 4.391

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.